Navigation Links
Licensee in Medical News

Clinical Trial by Licensee Does Not Meet Primary Endpoint

PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expan...

Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today

Company to Debut 'Dog Gone Smart(TM) Wear Brand Dog Apparel For the First Time in the U.S. at The Global Pet Expo February 14-16 SAN DIEGO, and WILTON, Conn., Feb. 13 /PRNewswire/ -- Nano Pet Products, LLC, a Wilton, Connecticut-based company dedicated to bringing cleaner and healthier ...

UI licensee Optherion secures $37 million in financing

Optherion, Inc., a University of Iowa Research Foundation licensee and a company developing products to diagnose and treat age-related macular degeneration (AMD) and other chronic diseases, today announced that it has completed $37 million startup financing. The company, which has offices and l...

Nuvo Announces 2009 second quarter financial results

...red to $4.3 million for the six months ended June 30, 2008. This increase is attributable to a $0.7 million increase in Pennsaid sales to our Canadian licensee and Greek distributor, the recognition of additional licensing fee revenue and higher research revenue. Gross margin on product sales declined sligh...

Blue Cross Blue Shield of Michigan, Michigan Attorney General and Michigan Office of Financial and Insurance Regulation Near Agreement on Rate Increases on Under Age 65 Individual Products

...ge as reasonably priced as possible, especially for those who need it most." Blue Cross Blue Shield of Michigan is nonprofit and an independent licensee of the Blue Cross and Blue Shield Association. ...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human an...

CareFirst Joins Partnership of Blues Plans as Owner of NASCO

...e turning to proven, scalable and affordable solutions like ours." About CareFirst In its 72nd year of service, CareFirst, an independent licensee of the Blue Cross and Blue Shield Association, is a not-for-profit health care organization which, through its affiliates and subsidiaries, offers a c...

State Regulation of Massage Therapy Will Improve Public Health, Safety

...oard to refuse, suspend or revoke a license if the licensee is convicted of a crime of moral turpitude or a felony, or if the licensee engages in immoral or unprofessional conduct. ...e act, or an individual who holds himself out as a licensee without being properly licensed. For additi...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

...t other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com . ...

Regence BlueShield of Idaho Announces Executive Changes

...ield of Oregon, Regence BlueCross BlueShield of Utah and Regence BlueShield (in selected counties in Washington). Each plan is a nonprofit independent licensee of the Blue Cross and Blue Shield Association. Regence is committed to improving the health of our members and our communities and to transforming our...
Licensee in Medical Technology

Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis, a licensee of Vical Incorporated (Nasdaq: VICL ), announced on Monday the initiation of a 500-patient Phase 3 clinical trial of its NV1FGF angiogenesis therapy, which is based on Vical's non-viral DNA delivery technology. Assuming ...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation Sciences, Inc. (T.A. Sciences) recently announced the results of the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial ever to show demonstrated, measurable and positive anti-aging benefits from a Telomerase Activator. Stati...

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company's licensee, AnGes MG, Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of an angiogenesis product candidate using Vical's D...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...t other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com . This press release includes f...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

...t other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com . This press release includes for...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...is. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human an...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...is. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human an...

Isis and Collaborators Present New Research at the ATVB Annual Conference

...t other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com . This press release includes for...

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds

...nstance, they have published successful results of a Phase II clinical trial in ear infections (otitis externa) using NCT. NovaBay expects Alcon, its licensee for the use of Aganocide compounds in the treatment of eye, ear, and sinus infections, to start human trials in the ear during 2009 with NovaBay's lea...

Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan

... Company extends the term and expands territorial rights of its exclusive licensee in Japan after Itochu reaches market penetration milestone of 100 customer manufacturers in Japan for cosmeceutical and dietary supplement products us...
Licensee in Biological News

GKSS membranes reduce air pollution in Beijing

... first systems have been installed in Shanghai, Beijing and Hunan. The GKSS licensee Borsig Membrane Technology GmbH is currently equipping about 140 filling st...ose membranes and the procedure is the GKSS Research Centre Geesthacht. The licensee for systems at filling stations and tank farms in Germany is Borsig Membran...
Licensee in Biological Technology

Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product

SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced the company's licensee, AnGes MG, Inc., reported submission on March 27, 2008, of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare for its angiogenesis product ca...

ADVENTRX Settles Dispute With Former Licensee

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) today announced that it settled its dispute with Theragenex, LLC and its Chairman and President and Chief Executive Officer for payments aggregating $600,000, which payments the Company has received in fu...

Micromet Closes $80.5 Million Public Offering of Common Stock

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a phase 1 clinical trial in 2009 with Micromet's glycolipid-binding human ...

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

...ted patents in its intellectual property portfolio of proprietary taste receptor technologies. As of June 30, 2009, Senomyx is the owner or exclusive licensee of 173 issued patents and 391 pending patent applications in the U.S., Europe, and elsewhere. Program Updates: - Savory Enhancer Progr...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human an...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...armaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosine in the North American market, has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol As...

Micromet Announces Pricing of Public Offering of Common Stock

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a phase 1 clinical trial in 2009 with Micromet's glycolipid-binding human ...

Micromet Announces Public Offering of Common Stock

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a phase 1 clinical trial in 2009 with Micromet's glycolipid-binding human ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human an...

Micromet Added to Russell 3000 Index

...umatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human an...
Licensee in Biological Dictionary

Cos site

...ance. Contact information and claims information. Find a Westfield Agent. ... Offers information for cosmetologists including forms, schools, and a licensee database. ... to distribute a video, you have to know what site is best for that genre of book. ... COS Productions and World Independent Film ...
Other Tags
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
(Date:8/21/2014)... News) -- In a new review of seafood safety, ... tuna due to concerns about mercury exposure. "We,re ... to shrimp as the most commonly eaten seafood in ... all tuna," Jean Halloran, director of food policy initiatives ... said in a news release from the group. ...
(Date:8/21/2014)... (HealthDay News) -- Using two types of polio vaccines ... may boost efforts to eradicate polio, a new study ... India found that giving the Salk inactivated poliovirus vaccine ... Sabin live-attenuated oral poliovirus vaccine (OPV) appeared to improve ... The findings, reported in the Aug. 22 issue of ...
(Date:8/21/2014)... 2014 The Onder Law Firm, nationally-renowned ... law, announces the launch of a new Morcellator Cancer ... morcellator surgery lawsuits for cancer claims, including ... warning and the July 2014 morcellator recall. , ... 2014 FDA warning on morcellator surgery and cancer, federal ...
(Date:8/21/2014)... 2014. Researchers have published a study examining racial ... with motor complete spinal cord injury (SCI). The ... discharge and follow-up among patients with motor complete ... August 2 by the Archives of Physical ... small but significant differences in self-care and mobility ...
Breaking Medicine News(10 mins):Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2
Other Contents